Fig. 1: Trial flow diagram illustrating patient assessment and allocation within the CLL7 study.

AIHA autoimmune hemolytic anemia, EFS event-free survival, FCR fludarabine, cyclophosphamide, and rituximab, PFS progression-free survival, OS overall survival, W&W watch and wait.